Carcinoid Heart Disease

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2020-02-05
Clinical Trial Update: Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome [Phase 3]
Phase 3 trial of lanreotide with telotristat ethyl or placebo for first-line treatment in advanced well-differentiated small intestinal neur…